Stem definition | Drug id | CAS RN |
---|---|---|
647 | 226256-56-0 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.19 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 17.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 18.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 19.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 22, 2004 | EMA | ||
March 8, 2004 | FDA | AMGEN |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hospitalisation | 8485.77 | 20.18 | 2554 | 24010 | 60831 | 46598667 |
Product dose omission issue | 6904.18 | 20.18 | 2805 | 23759 | 165715 | 46493783 |
Laboratory test abnormal | 6025.71 | 20.18 | 1572 | 24992 | 21275 | 46638223 |
Adverse drug reaction | 1364.56 | 20.18 | 610 | 25954 | 43752 | 46615746 |
Blood parathyroid hormone increased | 850.98 | 20.18 | 220 | 26344 | 2788 | 46656710 |
Intentional product misuse | 846.49 | 20.18 | 449 | 26115 | 46679 | 46612819 |
Blood parathyroid hormone abnormal | 470.29 | 20.18 | 85 | 26479 | 133 | 46659365 |
Hospice care | 336.53 | 20.18 | 123 | 26441 | 5172 | 46654326 |
Arteriovenous fistula site complication | 314.79 | 20.18 | 70 | 26494 | 437 | 46659061 |
Adverse event | 283.82 | 20.18 | 199 | 26365 | 33985 | 46625513 |
Living in residential institution | 254.15 | 20.18 | 56 | 26508 | 333 | 46659165 |
Calciphylaxis | 242.82 | 20.18 | 80 | 26484 | 2455 | 46657043 |
Hypocalcaemia | 215.49 | 20.18 | 153 | 26411 | 26632 | 46632866 |
Rehabilitation therapy | 209.70 | 20.18 | 60 | 26504 | 1132 | 46658366 |
Blood calcium increased | 193.91 | 20.18 | 92 | 26472 | 7495 | 46652003 |
Blood calcium decreased | 178.00 | 20.18 | 111 | 26453 | 15562 | 46643936 |
Decreased appetite | 174.97 | 20.18 | 358 | 26206 | 193478 | 46466020 |
Hypophagia | 168.48 | 20.18 | 137 | 26427 | 29169 | 46630329 |
Transplant | 161.45 | 20.18 | 43 | 26521 | 614 | 46658884 |
Death | 160.67 | 20.18 | 486 | 26078 | 335062 | 46324436 |
Malaise | 157.87 | 20.18 | 479 | 26085 | 330753 | 46328745 |
Abdominal discomfort | 156.67 | 20.18 | 296 | 26268 | 150869 | 46508629 |
Nausea | 153.82 | 20.18 | 782 | 25782 | 686672 | 45972826 |
Blood parathyroid hormone decreased | 152.80 | 20.18 | 66 | 26498 | 4315 | 46655183 |
Blood calcium abnormal | 149.89 | 20.18 | 43 | 26521 | 819 | 46658679 |
Parathyroidectomy | 145.62 | 20.18 | 33 | 26531 | 227 | 46659271 |
Unevaluable investigation | 122.40 | 20.18 | 21 | 26543 | 19 | 46659479 |
Renal transplant | 120.23 | 20.18 | 40 | 26524 | 1265 | 46658233 |
Rheumatoid arthritis | 115.47 | 20.18 | 5 | 26559 | 240210 | 46419288 |
Nephrogenic systemic fibrosis | 110.23 | 20.18 | 54 | 26510 | 4718 | 46654780 |
Hypercalcaemia | 109.73 | 20.18 | 93 | 26471 | 20953 | 46638545 |
Vomiting | 107.72 | 20.18 | 525 | 26039 | 452269 | 46207229 |
Parathyroid tumour benign | 102.91 | 20.18 | 30 | 26534 | 606 | 46658892 |
Fatigue | 88.86 | 20.18 | 131 | 26433 | 608566 | 46050932 |
Brown tumour | 85.35 | 20.18 | 16 | 26548 | 34 | 46659464 |
Blood phosphorus increased | 77.62 | 20.18 | 36 | 26528 | 2783 | 46656715 |
Gastrointestinal tube insertion | 74.73 | 20.18 | 27 | 26537 | 1096 | 46658402 |
Pyrexia | 72.00 | 20.18 | 56 | 26508 | 348746 | 46310752 |
Arthralgia | 70.97 | 20.18 | 62 | 26502 | 364541 | 46294957 |
Peritonitis bacterial | 70.86 | 20.18 | 50 | 26514 | 8603 | 46650895 |
Hungry bone syndrome | 69.87 | 20.18 | 12 | 26552 | 11 | 46659487 |
Mastication disorder | 69.40 | 20.18 | 30 | 26534 | 1964 | 46657534 |
Skin induration | 66.74 | 20.18 | 33 | 26531 | 2941 | 46656557 |
Blood phosphorus abnormal | 66.60 | 20.18 | 16 | 26548 | 146 | 46659352 |
Dialysis | 63.88 | 20.18 | 50 | 26514 | 10066 | 46649432 |
Condition aggravated | 54.89 | 20.18 | 36 | 26528 | 245016 | 46414482 |
Abdominal pain upper | 51.83 | 20.18 | 191 | 26373 | 145114 | 46514384 |
Pain | 50.67 | 20.18 | 124 | 26440 | 476824 | 46182674 |
Neutropenia | 50.60 | 20.18 | 10 | 26554 | 143194 | 46516304 |
Gastrostomy | 50.49 | 20.18 | 17 | 26547 | 558 | 46658940 |
Toxicity to various agents | 50.35 | 20.18 | 29 | 26535 | 211737 | 46447761 |
Arteriovenous fistula occlusion | 46.60 | 20.18 | 14 | 26550 | 315 | 46659183 |
Sinusitis | 45.98 | 20.18 | 9 | 26555 | 129759 | 46529739 |
Skin hypertrophy | 45.64 | 20.18 | 26 | 26538 | 3085 | 46656413 |
Drug ineffective | 45.01 | 20.18 | 216 | 26348 | 677622 | 45981876 |
Injection site pain | 43.52 | 20.18 | 5 | 26559 | 107147 | 46552351 |
Parathyroid disorder | 43.36 | 20.18 | 15 | 26549 | 535 | 46658963 |
Drug hypersensitivity | 43.24 | 20.18 | 45 | 26519 | 243780 | 46415718 |
Skin fibrosis | 42.26 | 20.18 | 17 | 26547 | 928 | 46658570 |
Joint swelling | 42.01 | 20.18 | 21 | 26543 | 166052 | 46493446 |
Skin tightness | 40.26 | 20.18 | 26 | 26538 | 3867 | 46655631 |
Unevaluable event | 39.97 | 20.18 | 84 | 26480 | 46091 | 46613407 |
Hyperparathyroidism | 39.85 | 20.18 | 22 | 26542 | 2457 | 46657041 |
Surgery | 38.29 | 20.18 | 63 | 26501 | 28722 | 46630776 |
Hyperphosphataemia | 38.28 | 20.18 | 19 | 26545 | 1707 | 46657791 |
Enteral nutrition | 37.98 | 20.18 | 8 | 26556 | 37 | 46659461 |
White blood cell count decreased | 37.28 | 20.18 | 9 | 26555 | 112222 | 46547276 |
Blue toe syndrome | 37.22 | 20.18 | 12 | 26552 | 343 | 46659155 |
Febrile neutropenia | 37.00 | 20.18 | 5 | 26559 | 94622 | 46564876 |
Treatment failure | 36.21 | 20.18 | 5 | 26559 | 93082 | 46566416 |
Chronic kidney disease-mineral and bone disorder | 36.14 | 20.18 | 11 | 26553 | 259 | 46659239 |
Gastrointestinal disorder | 35.84 | 20.18 | 94 | 26470 | 59482 | 46600016 |
Alanine aminotransferase increased | 33.82 | 20.18 | 5 | 26559 | 88446 | 46571052 |
Pelvic deformity | 33.03 | 20.18 | 10 | 26554 | 231 | 46659267 |
Hepatic enzyme increased | 32.76 | 20.18 | 4 | 26560 | 81783 | 46577715 |
Thyroid operation | 32.11 | 20.18 | 9 | 26555 | 157 | 46659341 |
Headache | 31.90 | 20.18 | 152 | 26412 | 478200 | 46181298 |
Fluid overload | 31.55 | 20.18 | 56 | 26508 | 27129 | 46632369 |
Arteriovenous fistula site infection | 30.78 | 20.18 | 7 | 26557 | 49 | 46659449 |
Neuropathy peripheral | 30.76 | 20.18 | 7 | 26557 | 90886 | 46568612 |
Joint contracture | 28.84 | 20.18 | 15 | 26549 | 1487 | 46658011 |
End stage renal disease | 28.61 | 20.18 | 25 | 26539 | 5861 | 46653637 |
Stomatitis | 28.20 | 20.18 | 3 | 26561 | 68294 | 46591204 |
Dyspnoea | 27.69 | 20.18 | 176 | 26388 | 515372 | 46144126 |
Weight increased | 27.32 | 20.18 | 32 | 26532 | 164441 | 46495057 |
Shunt stenosis | 26.92 | 20.18 | 9 | 26555 | 289 | 46659209 |
Aspartate aminotransferase increased | 26.75 | 20.18 | 6 | 26558 | 78694 | 46580804 |
Malignant neoplasm progression | 26.43 | 20.18 | 3 | 26561 | 64923 | 46594575 |
Platelet count decreased | 26.27 | 20.18 | 12 | 26552 | 100012 | 46559486 |
Dysphagia | 26.17 | 20.18 | 100 | 26464 | 77212 | 46582286 |
Peritonitis | 25.77 | 20.18 | 44 | 26520 | 20670 | 46638828 |
Upper respiratory tract infection | 25.72 | 20.18 | 3 | 26561 | 63553 | 46595945 |
Cardiac operation | 25.60 | 20.18 | 17 | 26547 | 2649 | 46656849 |
Wrong technique in product usage process | 25.07 | 20.18 | 78 | 26486 | 54344 | 46605154 |
Rash | 24.48 | 20.18 | 112 | 26452 | 356400 | 46303098 |
Arthropathy | 24.12 | 20.18 | 9 | 26555 | 84691 | 46574807 |
Drug interaction | 23.75 | 20.18 | 50 | 26514 | 203044 | 46456454 |
Hyperparathyroidism tertiary | 23.65 | 20.18 | 4 | 26560 | 3 | 46659495 |
Cough | 23.47 | 20.18 | 61 | 26503 | 230188 | 46429310 |
Intravascular haemolysis | 23.44 | 20.18 | 8 | 26556 | 274 | 46659224 |
Treatment noncompliance | 23.33 | 20.18 | 52 | 26512 | 29679 | 46629819 |
Therapeutic product effect decreased | 23.15 | 20.18 | 9 | 26555 | 82592 | 46576906 |
Parathyroid tumour malignant | 23.12 | 20.18 | 4 | 26560 | 4 | 46659494 |
Shunt occlusion | 23.03 | 20.18 | 9 | 26555 | 455 | 46659043 |
Migraine | 22.51 | 20.18 | 6 | 26558 | 70020 | 46589478 |
Hyperparathyroidism secondary | 22.34 | 20.18 | 12 | 26552 | 1270 | 46658228 |
Contusion | 22.20 | 20.18 | 11 | 26553 | 87476 | 46572022 |
Product use in unapproved indication | 21.95 | 20.18 | 12 | 26552 | 90261 | 46569237 |
Arteriovenous fistula site haemorrhage | 21.61 | 20.18 | 7 | 26557 | 203 | 46659295 |
Medical procedure | 21.58 | 20.18 | 7 | 26557 | 204 | 46659294 |
Gastric disorder | 21.29 | 20.18 | 47 | 26517 | 26658 | 46632840 |
Adjusted calcium decreased | 21.23 | 20.18 | 6 | 26558 | 108 | 46659390 |
Cerebrovascular accident | 20.91 | 20.18 | 113 | 26451 | 100926 | 46558572 |
Fibrosis | 20.76 | 20.18 | 17 | 26547 | 3647 | 46655851 |
Acute kidney injury | 20.74 | 20.18 | 67 | 26497 | 235788 | 46423710 |
Fall | 20.50 | 20.18 | 107 | 26457 | 328990 | 46330508 |
Wheezing | 20.45 | 20.18 | 3 | 26561 | 53383 | 46606115 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product dose omission issue | 7649.61 | 20.64 | 2726 | 18889 | 88905 | 29841958 |
Hospitalisation | 6899.06 | 20.64 | 2118 | 19497 | 42201 | 29888662 |
Laboratory test abnormal | 5920.74 | 20.64 | 1538 | 20077 | 15904 | 29914959 |
Adverse drug reaction | 1066.51 | 20.64 | 454 | 21161 | 22691 | 29908172 |
Intentional product misuse | 731.48 | 20.64 | 398 | 21217 | 34269 | 29896594 |
Blood parathyroid hormone increased | 644.34 | 20.64 | 158 | 21457 | 1220 | 29929643 |
Blood parathyroid hormone abnormal | 461.34 | 20.64 | 84 | 21531 | 93 | 29930770 |
Arteriovenous fistula site complication | 363.53 | 20.64 | 80 | 21535 | 356 | 29930507 |
Adverse event | 221.61 | 20.64 | 138 | 21477 | 15203 | 29915660 |
Transplant | 216.97 | 20.64 | 57 | 21558 | 595 | 29930268 |
Hospice care | 203.37 | 20.64 | 87 | 21528 | 4365 | 29926498 |
Blood parathyroid hormone decreased | 198.30 | 20.64 | 50 | 21565 | 437 | 29930426 |
Blood calcium increased | 194.62 | 20.64 | 76 | 21539 | 3011 | 29927852 |
Parathyroidectomy | 191.14 | 20.64 | 36 | 21579 | 55 | 29930808 |
Living in residential institution | 176.38 | 20.64 | 39 | 21576 | 178 | 29930685 |
Abdominal discomfort | 161.00 | 20.64 | 187 | 21428 | 48604 | 29882259 |
Blood calcium abnormal | 143.41 | 20.64 | 38 | 21577 | 411 | 29930452 |
Blood calcium decreased | 143.08 | 20.64 | 88 | 21527 | 9474 | 29921389 |
Hypocalcaemia | 137.76 | 20.64 | 118 | 21497 | 21258 | 29909605 |
Nausea | 136.41 | 20.64 | 496 | 21119 | 296461 | 29634402 |
Rehabilitation therapy | 127.86 | 20.64 | 37 | 21578 | 566 | 29930297 |
Blood phosphorus increased | 125.79 | 20.64 | 53 | 21562 | 2558 | 29928305 |
Hypophagia | 121.88 | 20.64 | 112 | 21503 | 22124 | 29908739 |
Calciphylaxis | 109.90 | 20.64 | 38 | 21577 | 1060 | 29929803 |
Vomiting | 109.10 | 20.64 | 377 | 21238 | 219441 | 29711422 |
Renal transplant | 102.13 | 20.64 | 41 | 21574 | 1747 | 29929116 |
Unevaluable investigation | 101.33 | 20.64 | 18 | 21597 | 15 | 29930848 |
Acute kidney injury | 99.23 | 20.64 | 37 | 21578 | 273805 | 29657058 |
Hypercalcaemia | 95.13 | 20.64 | 76 | 21539 | 12419 | 29918444 |
Toxicity to various agents | 85.45 | 20.64 | 13 | 21602 | 177170 | 29753693 |
Abdominal pain upper | 77.95 | 20.64 | 152 | 21463 | 62399 | 29868464 |
Pyrexia | 77.18 | 20.64 | 60 | 21555 | 294429 | 29636434 |
Malaise | 74.65 | 20.64 | 277 | 21338 | 166685 | 29764178 |
Parathyroid tumour benign | 73.57 | 20.64 | 17 | 21598 | 98 | 29930765 |
Parathyroid disorder | 66.49 | 20.64 | 14 | 21601 | 48 | 29930815 |
Death | 63.92 | 20.64 | 458 | 21157 | 356825 | 29574038 |
Surgery | 59.06 | 20.64 | 56 | 21559 | 11495 | 29919368 |
Gastrointestinal tube insertion | 55.10 | 20.64 | 24 | 21591 | 1257 | 29929606 |
Neutropenia | 54.36 | 20.64 | 13 | 21602 | 128527 | 29802336 |
Hyperparathyroidism secondary | 50.22 | 20.64 | 22 | 21593 | 1168 | 29929695 |
Gastrointestinal disorder | 48.71 | 20.64 | 79 | 21536 | 28058 | 29902805 |
Decreased appetite | 48.27 | 20.64 | 225 | 21390 | 149685 | 29781178 |
Mastication disorder | 47.83 | 20.64 | 21 | 21594 | 1121 | 29929742 |
Gastrostomy | 45.95 | 20.64 | 18 | 21597 | 718 | 29930145 |
Nephrogenic systemic fibrosis | 45.32 | 20.64 | 32 | 21583 | 4339 | 29926524 |
Hyperparathyroidism | 44.79 | 20.64 | 19 | 21596 | 932 | 29929931 |
Fatigue | 44.61 | 20.64 | 104 | 21511 | 320569 | 29610294 |
Adjusted calcium decreased | 43.64 | 20.64 | 7 | 21608 | 0 | 29930863 |
Hungry bone syndrome | 43.37 | 20.64 | 10 | 21605 | 57 | 29930806 |
Drug interaction | 41.33 | 20.64 | 50 | 21565 | 199518 | 29731345 |
Shunt occlusion | 41.24 | 20.64 | 16 | 21599 | 622 | 29930241 |
Gastric disorder | 40.86 | 20.64 | 44 | 21571 | 10499 | 29920364 |
Blood phosphorus abnormal | 39.80 | 20.64 | 11 | 21604 | 141 | 29930722 |
Hyperphosphataemia | 39.52 | 20.64 | 23 | 21592 | 2236 | 29928627 |
Dialysis | 39.33 | 20.64 | 44 | 21571 | 10952 | 29919911 |
Unevaluable event | 38.05 | 20.64 | 76 | 21539 | 31709 | 29899154 |
Platelet count decreased | 37.22 | 20.64 | 15 | 21600 | 106114 | 29824749 |
Treatment noncompliance | 35.93 | 20.64 | 65 | 21550 | 25188 | 29905675 |
Dyspnoea | 34.68 | 20.64 | 124 | 21491 | 333171 | 29597692 |
Peritonitis bacterial | 33.17 | 20.64 | 41 | 21574 | 11337 | 29919526 |
Overdose | 32.86 | 20.64 | 10 | 21605 | 84327 | 29846536 |
Condition aggravated | 32.45 | 20.64 | 31 | 21584 | 137835 | 29793028 |
Leg amputation | 32.26 | 20.64 | 20 | 21595 | 2181 | 29928682 |
Confusional state | 32.11 | 20.64 | 30 | 21585 | 134804 | 29796059 |
Hyperparathyroidism tertiary | 31.17 | 20.64 | 5 | 21610 | 0 | 29930863 |
White blood cell count decreased | 30.87 | 20.64 | 11 | 21604 | 83936 | 29846927 |
Appetite disorder | 30.85 | 20.64 | 18 | 21597 | 1758 | 29929105 |
Alanine aminotransferase increased | 30.43 | 20.64 | 8 | 21607 | 74268 | 29856595 |
Hyponatraemia | 30.00 | 20.64 | 6 | 21609 | 67196 | 29863667 |
Shunt stenosis | 30.00 | 20.64 | 11 | 21604 | 365 | 29930498 |
Dehydration | 29.99 | 20.64 | 27 | 21588 | 123512 | 29807351 |
Haemoglobin increased | 29.52 | 20.64 | 21 | 21594 | 2881 | 29927982 |
Anaemia | 29.22 | 20.64 | 67 | 21548 | 207925 | 29722938 |
Pulmonary embolism | 29.14 | 20.64 | 10 | 21605 | 78125 | 29852738 |
Disease progression | 28.47 | 20.64 | 11 | 21604 | 79863 | 29851000 |
Skin induration | 27.16 | 20.64 | 18 | 21597 | 2201 | 29928662 |
Thyroid operation | 26.80 | 20.64 | 5 | 21610 | 7 | 29930856 |
Rhabdomyolysis | 25.76 | 20.64 | 7 | 21608 | 63573 | 29867290 |
Thrombocytopenia | 25.61 | 20.64 | 37 | 21578 | 137007 | 29793856 |
Plasma cell myeloma | 25.54 | 20.64 | 4 | 21611 | 53458 | 29877405 |
Pancytopenia | 25.29 | 20.64 | 15 | 21600 | 85037 | 29845826 |
Brown tumour | 24.94 | 20.64 | 4 | 21611 | 0 | 29930863 |
Parathyroid tumour malignant | 24.94 | 20.64 | 4 | 21611 | 0 | 29930863 |
Parathyroid hyperplasia | 24.94 | 20.64 | 4 | 21611 | 0 | 29930863 |
Neuropathy peripheral | 24.63 | 20.64 | 10 | 21605 | 70465 | 29860398 |
Aspartate aminotransferase increased | 23.85 | 20.64 | 8 | 21607 | 63414 | 29867449 |
Wrong technique in product usage process | 23.41 | 20.64 | 62 | 21553 | 31093 | 29899770 |
Product use in unapproved indication | 23.35 | 20.64 | 12 | 21603 | 73681 | 29857182 |
Calcinosis | 22.99 | 20.64 | 11 | 21604 | 717 | 29930146 |
Tachycardia | 21.93 | 20.64 | 13 | 21602 | 73726 | 29857137 |
Weight decreased | 20.86 | 20.64 | 49 | 21566 | 150872 | 29779991 |
Source | Code | Description |
---|---|---|
ATC | H05BX01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents |
FDA MoA | N0000020081 | Increased Calcium-sensing Receptor Sensitivity |
MeSH PA | D057966 | Calcimimetic Agents |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D006727 | Hormone Antagonists |
FDA EPC | N0000175902 | Calcium-sensing Receptor Agonist |
CHEBI has role | CHEBI:48525 | calcimimetics |
CHEBI has role | CHEBI:50183 | cytochrome p450 inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercalcemia due to Primary Hyperparathyroidism | indication | ||
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis | indication | ||
Parathyroid Carcinoma with Hypercalcemia | indication | ||
Hypophosphatemia | contraindication | 4996001 | |
Hypocalcemia | contraindication | 5291005 | |
Low blood pressure | contraindication | 45007003 | |
Chronic heart failure | contraindication | 48447003 | |
Seizure disorder | contraindication | 128613002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Adynamic bone disease | contraindication | 236552002 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.69 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 30MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | Nov. 21, 2021 | TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNULLBLE TO UNDERGO PARATHYROIDECTOMY. |
EQ 60MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | Nov. 21, 2021 | TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNULLBLE TO UNDERGO PARATHYROIDECTOMY. |
EQ 90MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | Nov. 21, 2021 | TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNULLBLE TO UNDERGO PARATHYROIDECTOMY. |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Extracellular calcium-sensing receptor | GPCR | POSITIVE ALLOSTERIC MODULATOR | EC50 | 7.70 | CHEMBL | CHEMBL | |||
Glycine receptor subunit alpha-1 | Ion channel | EC50 | 6.49 | CHEMBL |
ID | Source |
---|---|
4021430 | VUID |
N0000148841 | NUI |
D03504 | KEGG_DRUG |
364782-34-3 | SECONDARY_CAS_RN |
4021430 | VANDF |
C1260201 | UMLSCUI |
CHEBI:48390 | CHEBI |
CHEMBL1201284 | ChEMBL_ID |
CHEMBL1200776 | ChEMBL_ID |
DB01012 | DRUGBANK_ID |
D000069449 | MESH_DESCRIPTOR_UI |
156418 | PUBCHEM_CID |
3308 | IUPHAR_LIGAND_ID |
8287 | INN_ID |
UAZ6V7728S | UNII |
384379 | RXNORM |
18133 | MMSL |
303128 | MMSL |
49840 | MMSL |
d05218 | MMSL |
008595 | NDDF |
008596 | NDDF |
409391006 | SNOMEDCT_US |
409392004 | SNOMEDCT_US |
426512007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7067 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 25 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-078 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-079 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-080 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 27 sections |
CINULLCALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-440 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 25 sections |
CINULLCALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-441 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 25 sections |
CINULLCALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-442 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 25 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-103 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 29 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-104 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 29 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-105 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 29 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-961 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-962 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-963 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-367 | TABLET | 30 mg | ORAL | ANDA | 24 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-368 | TABLET | 60 mg | ORAL | ANDA | 24 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-369 | TABLET | 90 mg | ORAL | ANDA | 24 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-379 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-380 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-600 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 27 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3529 | TABLET, COATED | 30 mg | ORAL | NDA | 28 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4470 | TABLET, COATED | 30 mg | ORAL | NDA | 26 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-295 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-296 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-297 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 23 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0577 | TABLET, COATED | 30 mg | ORAL | NDA | 26 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0578 | TABLET, COATED | 60 mg | ORAL | NDA | 26 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5616 | TABLET, COATED | 30 mg | ORAL | NDA | 22 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-073 | TABLET, COATED | 30 mg | ORAL | NDA | 27 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-074 | TABLET, COATED | 60 mg | ORAL | NDA | 27 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-075 | TABLET, COATED | 90 mg | ORAL | NDA | 27 sections |